Ibnsina Pharma announced it signed two contracts with Novo Nordisk to distribute over 20 stock-keeping units of its diabetes care, haemophilia, and growth disorders products in Egypt. Ibnsina says it invested EGP 2 mn in additional warehousing facilities to deliver Novo Nordisk’s cold-chain products and that the investment is the first execution in our plan to invest EGP 700 mn over the next five years in new sites and expansions.

Tags: